ClinicalTrials.gg
RecruitingNCT00082108Updated Oct 15, 2025

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

An observational study in Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy and Muscular Dystrophy, sponsored by University of Rochester. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by University of Rochester · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
3rd of 21
3,000 · median 125
Started
2000
the only one that year
Observational
21 of 43
15 open now
Primary completion
2028-06
later than 11 of 26 live
Registered
1st of 43
by date
Lead sponsor
6 of 43
University of Rochester

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 3rd largest by planned enrollment of the 21 observational ones that give a count, is the only one that started in 2000, is one of 21 observational ones, reaches primary completion later than 11 of the 26 other live ones, and was the 1st registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their diseases. The registry will also help scientists to accomplish research on DM and FSHD and to distribute their findings to patients and care providers.

Read the detailed description

The National Registry of DM and FSHD Patients and Family Members was developed to create a link between patients and scientists in order to promote research on these rare illnesses. The Registry is sponsored by the National Institutes of Health.

Patients that are interested in joining the Registry can email or call to request an application or download the forms from the website (www.dystrophyregistry.org). The Application packet contains:

  • A Patient Information Form, which asks about your muscle strength, general health, and how your disease affects your daily life
  • A Medical Records Release Form, which allows us to contact your doctor and obtain records about your diagnosis
  • An informed Consent Form, which describes the study's purpose and what you can expect while you are involved with the project.

After you are enrolled in the Registry, there are several ways to participate in research. The activities include:

  • Complete an annual update form to help us keep track of how your symptoms change over time.
  • Receive updates about the progress of the Registry, research highlights, and other news related to muscular dystrophy through newsletters, an email listserv, and Facebook.
  • Receive letters from the Registry when researchers are looking for patients to take part in studies. These projects may include filling out questionnaires, exploring new treatments, and other types of research.

There is no obligation to participate in these activities. Taking part in any study or filling out the annual updates are completely up to you.

03

Conditions studied

  • Myotonic Dystrophy
  • Facioscapulohumeral Muscular Dystrophy
  • Muscular Dystrophy
  • Myotonic Dystrophy Type 1
  • Myotonic Dystrophy Type 2
  • Congenital Myotonic Dystrophy
  • PROMM (Proximal Myotonic Myopathy)
  • Steinert's Disease
  • Myotonic Muscular Dystrophy

Keywords

  • Registry
  • FSHD
  • DM
  • Muscular Dystrophy
  • Facioscapulohumeral Myotonic Dystrophy
  • Myotonic Dystrophy
  • DM1
  • DM2
  • FSH
  • MMD
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will volunteer to participate in this study. The study will be advertised through neuromuscular disease clinics, the National Registry website, Patient Advocacy Groups and MDA Clinics through out the United States.

Eligibility criteria

Inclusion Criteria:

  • Diagnosed with DM, FSHD, or related diseases or are an unaffected family member of someone diagnosed with one of these diseases
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
06

What researchers measure

Primary outcomes

  1. Patient reported outcomes

    Time frame: Annual

07

Study locations

1 of 1 sites recruiting
  • University of Rochester Medical Center, Department of Neurology
    Rochester, New York 14642, United States
    Recruiting
    • Registry Coordinator · Contactdystrophy_registry@urmc.rochester.edu · 888-925-4302
    • Richard T. Moxley, III, MD · Principal investigator
    • Rabi Tawil, MD · Sub investigator
    • Charles Thornton, MD · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000, a primary completion of Jun 2028 and a completion of Jun 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2004
First posted
Apr 30, 2004
Start
Sep 2000
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00082108
Responsible party
Johanna Hamel (Associate Professor of Neurology, University of Rochester) — Principal investigator
First posted
Apr 30, 2004
Start date
Sep 2000
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 15, 2025

Study contacts

Registry Coordinator
Contact
dystrophy_registry@urmc.rochester.edu
888-925-4302
Johann Hamel, MD
principal investigator · University of Rochester Medical Center, Department of Neurology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion